News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,800 Results
Type
Article (41516)
Company Profile (461)
Press Release (656823)
Section
Business (208351)
Career Advice (1999)
Deals (35936)
Drug Delivery (91)
Drug Development (83269)
Employer Resources (169)
FDA (16324)
Job Trends (15037)
News (352005)
Policy (32972)
Tag
Academia (2619)
Alliances (50557)
Alzheimer's disease (1260)
Approvals (16236)
Artificial intelligence (125)
Bankruptcy (361)
Best Places to Work (11663)
Biotechnology (346)
Breast cancer (111)
Cancer (933)
Cardiovascular disease (85)
Career advice (1669)
Cell therapy (213)
Clinical research (65679)
Collaboration (345)
Compensation (170)
COVID-19 (2582)
Data (881)
Diabetes (138)
Diagnostics (6155)
Drug pricing (83)
Earnings (85385)
Employer resources (147)
Events (112290)
Executive appointments (252)
FDA (16775)
Funding (303)
Gene therapy (163)
GLP-1 (594)
Government (4403)
Healthcare (18977)
Infectious disease (2657)
Inflammatory bowel disease (108)
Interviews (308)
IPO (16547)
Job creations (3693)
Job search strategy (1427)
Layoffs (434)
Legal (7923)
Lung cancer (158)
Manufacturing (155)
Medical device (13295)
Medtech (13300)
Mergers & acquisitions (19400)
Metabolic disorders (388)
Neuroscience (1514)
NextGen Class of 2024 (6730)
Non-profit (4530)
Northern California (1224)
Obesity (230)
Opinion (195)
Patents (95)
People (57481)
Pharmaceutical (87)
Phase I (20555)
Phase II (28981)
Phase III (21464)
Pipeline (215)
Postmarket research (2591)
Preclinical (8818)
Radiopharmaceuticals (250)
Rare diseases (193)
Real estate (5996)
Regulatory (21879)
Research institute (2402)
Resumes & cover letters (351)
Southern California (1104)
Startups (3745)
United States (12062)
Vaccines (554)
Weight loss (176)
Date
Today (242)
Last 7 days (872)
Last 30 days (3020)
Last 365 days (36776)
2024 (31374)
2023 (41013)
2022 (52276)
2021 (56765)
2020 (54924)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (195)
Asia (38403)
Australia (6382)
California (2820)
Canada (1185)
China (212)
Colorado (120)
Connecticut (131)
Europe (83717)
Florida (397)
Georgia (100)
Illinois (318)
Indiana (180)
Kansas (98)
Maryland (528)
Massachusetts (2343)
Michigan (145)
Minnesota (256)
New Jersey (844)
New York (856)
North Carolina (723)
Northern California (1224)
Ohio (128)
Pennsylvania (755)
South America (1105)
Southern California (1104)
Texas (397)
Washington State (335)
698,800 Results for "novelmed therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Drug Development
NovelMed Commences Phase II Trial for Anti-Bb Antibody (NM8074) in Treatment-Naïve PNH Patients: A Glimpse into the PNH Study Progress
NovelMed Therapeutics is excited to announce the commencement of its Phase II clinical trial targeting treatment-naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) patients with its groundbreaking anti-Bb antibody, NM8074.
October 30, 2023
·
5 min read
Drug Development
NovelMed Phase I Clinical Trial Shows Inhibition of the Alternative Pathway and Preservation of the Classical Pathway – A Long-Acting Anti-Properdin Monoclonal Antibody NM3086 for PNH Patients
NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin antibody, known as NM3086.
June 5, 2023
·
6 min read
Press Releases
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
October 8, 2024
·
14 min read
FDA
FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic Rare Disease in Nephrology
NovelMed proudly announces the U.S. Food and Drug Administration’s (FDA) clearance on Ruxoprubart, the investigational drug, for commencing an efficacy trial targeting patients with ANCA Associated Vasculitis (AAV), a rare autoimmune chronic ailment characterized by inflammation in small blood vessels.
June 17, 2024
·
6 min read
Business
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.
June 27, 2024
·
5 min read
Press Releases
ReCerise Therapeutics Inc. Selected for Government Project by MOTIE
Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.
July 1, 2024
·
2 min read
Pharm Country
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.
May 22, 2024
·
7 min read
Press Releases
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
October 28, 2024
·
8 min read
Press Releases
ME Therapeutics Holdings Inc. Appoints Chief Business Officer
October 25, 2024
·
4 min read
1 of 69,880
Next
